Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 731–740 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 731
- Medicine slug
- icatibant
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
97%
- Numeric value
- 97
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed6657ca-ab68-477a-9968-e12dc928b540 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
The absolute bioavailability of FIRAZYR following a 30 mg subcutaneous dose is approximately 97%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a53361-4eda-4e30-a153-44cd142983dd (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
The absolute bioavailability of icatibant following a 30 mg subcutaneous dose is approximately 97%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402a20e0-d1e2-4a24-ae1d-f2ff6d8fa7b3 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
The absolute bioavailability of icatibant following a 30 mg subcutaneous dose is approximately 97%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d5047e-3f99-4100-af4f-388870986ced (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
The absolute bioavailability of icatibant following a 30 mg subcutaneous dose is approximately 97%.
Projected row 732
- Medicine slug
- icatibant
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
1.4 ± 0.4 hours
- Numeric value
- 1.4
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aeb5406c-9501-4f43-8134-5b02a7fa7451 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed6657ca-ab68-477a-9968-e12dc928b540 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a53361-4eda-4e30-a153-44cd142983dd (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402a20e0-d1e2-4a24-ae1d-f2ff6d8fa7b3 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52c12c15-c00b-4efc-952d-1425c907706a (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c149392-d281-4311-880f-3be2b4752f40 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccbb5e50-ce56-4898-aa1a-f1c1f3d312f6 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d5047e-3f99-4100-af4f-388870986ced (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1756aca0-21a1-4898-8d6c-9666738db45c (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
Projected row 733
- Medicine slug
- icatibant
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
29.0 ± 8.7 L
- Numeric value
- 29
- Unit
- L
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aeb5406c-9501-4f43-8134-5b02a7fa7451 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed6657ca-ab68-477a-9968-e12dc928b540 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94a53361-4eda-4e30-a153-44cd142983dd (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402a20e0-d1e2-4a24-ae1d-f2ff6d8fa7b3 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52c12c15-c00b-4efc-952d-1425c907706a (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c149392-d281-4311-880f-3be2b4752f40 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccbb5e50-ce56-4898-aa1a-f1c1f3d312f6 (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d5047e-3f99-4100-af4f-388870986ced (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1756aca0-21a1-4898-8d6c-9666738db45c (opens source in a new tab)
Icatibant label
Version not recorded · Effective date not recorded
Following subcutaneous administration, plasma clearance was 245 ± 58 mL/min with a mean elimination half-life of 1.4 ± 0.4 hours and volume of distribution at steady state (V ss ) of 29.0 ± 8.7 L.
Projected row 734
- Medicine slug
- icosapent-ethyl
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
89 hours
- Numeric value
- 89
- Unit
- hours
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07631e74-48e5-46ec-b8db-4b1bcf62d283 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e3498ab-f35e-4597-8556-89bf9fdd1406 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30574162-0e84-4352-b7fa-42fc20115d68 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ee78f22-bed2-48f8-9be8-b8f6ceeeaeaf (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a1ca8a-2d22-4c54-9193-eab4e75ba7db (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45f8bb41-bdb1-4afc-83ec-9dc69720ee9c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:582638e5-9881-409d-a455-041b5ba6892a (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6db749b9-c817-41cd-909f-dd60a90c9f73 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b30afc7a-bffb-4c71-974f-1d977156eb46 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd28217d-5817-43b0-8185-7c7ec6da83f3 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1aca884c-c464-900d-ac06-33aee7118df8 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t1/2) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdcee03e-5df1-a8fc-7490-dfdc624ce6d6 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t1/2) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3637187f-70bc-eb31-e063-6294a90ad3cb (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd2b5373-1ddd-46c0-a579-d5a4f289d79f (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d245ddab-d81b-44bd-90d7-0e4d446d9bf5 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c3e26d6-9297-42ad-94b4-04e394155b41 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5910742b-c5e6-4029-9a19-97669e3808bc (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc28828d-beab-45cc-a3b6-151c5fee3924 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t1/2) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6e361cc-c314-4402-9361-2d977788e93c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3d38d1d-fbe7-413d-849a-675e7dfa9b0a (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:886aa8d8-b293-258f-b16d-be40418787a8 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de7049ae-d1d6-4267-a93b-dd5039c50c2c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1a2828-1583-4414-ab22-a60480e8e508 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24105b33-bbb7-4349-a5d0-8fe4af7e4994 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20686acb-66c5-4d75-9684-7474436e8bef (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:019cc0ac-0c2f-426d-996a-6d932f954443 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5b0b1ae-29ab-43a5-9e6d-24374d961399 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c1a6a6-cda4-49ea-97e9-0d3cf5ab5d4c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
The plasma elimination half-life (t 1/2 ) of EPA is approximately 89 hours.
Projected row 735
- Medicine slug
- icosapent-ethyl
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07631e74-48e5-46ec-b8db-4b1bcf62d283 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e3498ab-f35e-4597-8556-89bf9fdd1406 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30574162-0e84-4352-b7fa-42fc20115d68 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ee78f22-bed2-48f8-9be8-b8f6ceeeaeaf (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a1ca8a-2d22-4c54-9193-eab4e75ba7db (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45f8bb41-bdb1-4afc-83ec-9dc69720ee9c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:582638e5-9881-409d-a455-041b5ba6892a (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6db749b9-c817-41cd-909f-dd60a90c9f73 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b30afc7a-bffb-4c71-974f-1d977156eb46 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd28217d-5817-43b0-8185-7c7ec6da83f3 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1aca884c-c464-900d-ac06-33aee7118df8 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdcee03e-5df1-a8fc-7490-dfdc624ce6d6 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3637187f-70bc-eb31-e063-6294a90ad3cb (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd2b5373-1ddd-46c0-a579-d5a4f289d79f (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d245ddab-d81b-44bd-90d7-0e4d446d9bf5 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of VASCEPA.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c3e26d6-9297-42ad-94b4-04e394155b41 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5910742b-c5e6-4029-9a19-97669e3808bc (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc28828d-beab-45cc-a3b6-151c5fee3924 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6e361cc-c314-4402-9361-2d977788e93c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3d38d1d-fbe7-413d-849a-675e7dfa9b0a (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:886aa8d8-b293-258f-b16d-be40418787a8 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de7049ae-d1d6-4267-a93b-dd5039c50c2c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1a2828-1583-4414-ab22-a60480e8e508 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of VASCEPA.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24105b33-bbb7-4349-a5d0-8fe4af7e4994 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20686acb-66c5-4d75-9684-7474436e8bef (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:019cc0ac-0c2f-426d-996a-6d932f954443 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5b0b1ae-29ab-43a5-9e6d-24374d961399 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c1a6a6-cda4-49ea-97e9-0d3cf5ab5d4c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of EPA were reached approximately 5 hours following oral doses of icosapent ethyl.
Projected row 736
- Medicine slug
- icosapent-ethyl
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
88 liters
- Numeric value
- 88
- Unit
- L
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07631e74-48e5-46ec-b8db-4b1bcf62d283 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e3498ab-f35e-4597-8556-89bf9fdd1406 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30574162-0e84-4352-b7fa-42fc20115d68 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ee78f22-bed2-48f8-9be8-b8f6ceeeaeaf (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a1ca8a-2d22-4c54-9193-eab4e75ba7db (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45f8bb41-bdb1-4afc-83ec-9dc69720ee9c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:582638e5-9881-409d-a455-041b5ba6892a (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6db749b9-c817-41cd-909f-dd60a90c9f73 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b30afc7a-bffb-4c71-974f-1d977156eb46 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd28217d-5817-43b0-8185-7c7ec6da83f3 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1aca884c-c464-900d-ac06-33aee7118df8 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdcee03e-5df1-a8fc-7490-dfdc624ce6d6 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3637187f-70bc-eb31-e063-6294a90ad3cb (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd2b5373-1ddd-46c0-a579-d5a4f289d79f (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d245ddab-d81b-44bd-90d7-0e4d446d9bf5 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c3e26d6-9297-42ad-94b4-04e394155b41 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5910742b-c5e6-4029-9a19-97669e3808bc (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc28828d-beab-45cc-a3b6-151c5fee3924 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6e361cc-c314-4402-9361-2d977788e93c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3d38d1d-fbe7-413d-849a-675e7dfa9b0a (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:886aa8d8-b293-258f-b16d-be40418787a8 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de7049ae-d1d6-4267-a93b-dd5039c50c2c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1a2828-1583-4414-ab22-a60480e8e508 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24105b33-bbb7-4349-a5d0-8fe4af7e4994 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady-state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20686acb-66c5-4d75-9684-7474436e8bef (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:019cc0ac-0c2f-426d-996a-6d932f954443 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5b0b1ae-29ab-43a5-9e6d-24374d961399 (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c1a6a6-cda4-49ea-97e9-0d3cf5ab5d4c (opens source in a new tab)
Icosapent Ethyl label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution at steady state of EPA is approximately 88 liters.
Projected row 737
- Medicine slug
- idarubicin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 0.75
- Recorded readings
22 hours
- Numeric value
- 22
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9b337d5-50f7-4ea9-9df4-72c86e4c0b91 (opens source in a new tab)
Idarubicin label
Version not recorded · Effective date not recorded
The elimination rate of idarubicin from plasma is slow with an estimated mean terminal half-life of 22 hours (range, 4 to 48 hours) when used as a single agent and 20 hours (range, 7 to 38 hours) when used in combination with cytarabine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d31254be-6bd2-4ac1-acab-bc00e2209d28 (opens source in a new tab)
Idarubicin label
Version not recorded · Effective date not recorded
The elimination rate of idarubicin from plasma is slow with an estimated mean terminal half-life of 22 hours (range, 4 to 48 hours) when used as a single agent and 20 hours (range, 7 to 38 hours) when used in combination with cytarabine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c20b574-285b-49eb-a98e-6752e4bb481d (opens source in a new tab)
Idarubicin label
Version not recorded · Effective date not recorded
The elimination rate of idarubicin from plasma is slow with an estimated mean terminal half-life of 22 hours (range, 4 to 48 hours) when used as a single agent and 20 hours (range, 7 to 38 hours) when used in combination with cytarabine.
45 hours
- Numeric value
- 45
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a5a6d93-cc1e-4d7f-8da1-446c134503b3 (opens source in a new tab)
Idarubicin label
Version not recorded · Effective date not recorded
Idarubicinol mean terminal half-life exceeds 45 hours; hence, its plasma levels are sustained for a period greater than 8 days.
Projected row 738
- Medicine slug
- idarubicin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
97%
- Numeric value
- 97
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9b337d5-50f7-4ea9-9df4-72c86e4c0b91 (opens source in a new tab)
Idarubicin label
Version not recorded · Effective date not recorded
The percentages of idarubicin and idarubicinol bound to human plasma proteins averaged 97% and 94%, respectively, at concentrations similar to maximum plasma levels obtained in the pharmacokinetic studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d31254be-6bd2-4ac1-acab-bc00e2209d28 (opens source in a new tab)
Idarubicin label
Version not recorded · Effective date not recorded
The percentages of idarubicin and idarubicinol bound to human plasma proteins averaged 97% and 94%, respectively, at concentrations similar to maximum plasma levels obtained in the pharmacokinetic studies.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c20b574-285b-49eb-a98e-6752e4bb481d (opens source in a new tab)
Idarubicin label
Version not recorded · Effective date not recorded
The percentages of idarubicin and idarubicinol bound to human plasma proteins averaged 97% and 94%, respectively, at concentrations similar to maximum plasma levels obtained in the pharmacokinetic studies.
Projected row 739
- Medicine slug
- ifosfamide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
15 hours
- Numeric value
- 15
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7241707-7538-4d1a-91e7-3a25a91e0b9a (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
At single doses of 3.8 to 5.0 g/m 2 , the plasma concentrations decay biphasically and the mean terminal elimination half-life is about 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c90ab05f-8fe5-437e-a1c0-8b11ef63291e (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
At single doses of 3.8 to 5 g/m2, the plasma concentrations decay biphasically and themean terminal elimination half-life is about 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a311a947-7b78-4226-bfe0-f4aa0be20e27 (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
At single doses of 3.8 to 5.0 g/m 2 , the plasma concentrations decay biphasically and the mean terminal elimination half-life is about 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efb1d03b-2d91-406e-8110-d3a58b8fa7cc (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
At single doses of 3.8 to 5.0 g/m 2 , the plasma concentrations decay biphasically and the mean terminal elimination half-life is about 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91e433a9-6800-43a6-ac13-a49a04a5aecd (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
At single doses of 3.8 to 5.0 g/m 2 , the plasma concentrations decay biphasically and the mean terminal elimination half-life is about 15 hours.
Projected row 740
- Medicine slug
- ifosfamide
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
2.4±0.33 L
- Numeric value
- 2.4
- Unit
- L
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7241707-7538-4d1a-91e7-3a25a91e0b9a (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
The mean±standard error population estimates for the initial clearance and volume of distribution of ifosfamide were 2.4±0.33 L/h/m 2 and 21±1.6 L/m 2 with an interindividual variability of 43% and 32%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c90ab05f-8fe5-437e-a1c0-8b11ef63291e (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
The mean ± standard error population estimates for the initial clearance and volume of distribution of ifosfamide were 2.4±0.33 L/h/m 2 and 21±1.6 L/m 2 with an interindividual variability of 43% and 32%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a311a947-7b78-4226-bfe0-f4aa0be20e27 (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
The mean±standard error population estimates for the initial clearance and volume of distribution of ifosfamide were 2.4±0.33 L/h/m 2 and 21±1.6 L/m 2 with an interindividual variability of 43% and 32%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efb1d03b-2d91-406e-8110-d3a58b8fa7cc (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
The mean±standard error population estimates for the initial clearance and volume of distribution of ifosfamide were 2.4±0.33 L/h/m 2 and 21±1.6 L/m 2 with an interindividual variability of 43% and 32%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91e433a9-6800-43a6-ac13-a49a04a5aecd (opens source in a new tab)
Ifosfamide label
Version not recorded · Effective date not recorded
The mean±standard error population estimates for the initial clearance and volume of distribution of ifosfamide were 2.4±0.33 L/h/m 2 and 21±1.6 L/m 2 with an interindividual variability of 43% and 32%, respectively.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=730Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.